ABOUT INTEGRAL MOLECULAR

Integral Molecular is a research-driven biotechnology company creating innovative technologies and therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes.

November 12, 2015

Integral Molecular identifies key molecular interactions responsible for the effectiveness of the ZMapp™ anti-Ebola virus cocktail

To support the creation of Ebola virus vaccines and treatments, Integral Molecular, a leader in membrane protein antibody discovery, has identified the key molecular interactions that […]
October 15, 2015

Integral Molecular awarded $5.5M by the National Institutes of Health to study Ebola antibodies to aid in vaccine discovery

With a new $5.5M award from the National Institute of Allergy and Infectious Diseases (NIAID) part of the National Institutes of Health (NIH), Integral Molecular, Inc. […]
July 3, 2015

Cat got your tongue? Not according to new research

The ability to detect bitter chemicals is thought to have evolved because it helps animals avoid toxic compounds often found in plants. All cats, from pets […]
December 10, 2014

Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, a leader in membrane protein antibody discovery, in conjunction with Blood Systems Research Institute (BSRI), has identified potent inhibitory human antibodies against the […]
November 13, 2014

Integral Molecular awarded $3.5M contract from NIH to study Ebola and Hepatitis C virus antibody response

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, Inc. has been awarded a five year $3.5 million contract to study the human immune response to Ebola virus and hepatitis C virus […]
July 17, 2014

Integral Molecular Announces Patent Allowance for Dengue Research Technology

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, a leader in membrane protein research, announces the issuance of a new composition patent protecting dengue reporter virus particles (RVPs). The invention relates […]
March 28, 2014

Integral Molecular announces patent protecting the use of Lipoparticles for antibody discovery

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent protecting the use of Lipoparticles for eliciting antibodies against […]
December 11, 2013

Integral Molecular identifies potent antibody antagonists against ion channel pain target P2X3

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, a leader in membrane protein antibody discovery, announces that it has successfully generated potent antibody antagonists targeting the P2X3 ion channel using the […]
November 6, 2013

Integral Molecular Announces Issuance of Third Patent Family, Extending Patent Landscape for Key Lipoparticle Technology

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent and patent family protecting the composition of matter for […]
April 22, 2013

Integral Molecular Launches MPS Platform for Discovery of Antibodies Targeting Membrane Proteins

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, Inc., a leader in membrane protein reagents and services, announces the launch of its Membrane Protein Solutions (MPS) antibody discovery platform. MPS enables […]
February 20, 2013

Patent for Nano-scale Detection of Ion Channel Function in Lipoparticles

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, Inc., a leader in membrane protein reagents and services, announces a patent allowance covering its technology for cell-free detection of ion channel function. […]
December 3, 2012

Integral Molecular and IntelliCyt Corporation Announce Co-marketing Collaboration

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular and IntelliCyt Corporation today announced the formation of a collaborative marketing alliance to co-promote Integral’s Shotgun Mutagenesis protein mapping and engineering platform and […]
November 15, 2012

Integral Molecular and Crystal Bioscience Announce Research Collaboration to Develop Novel GPCR and Ion Channel Antibodies

PHILADELPHIA–(BUSINESS WIRE)–Crystal Bioscience and Integral Molecular have launched a research collaboration to generate panels of chicken monoclonal antibodies against undisclosed therapeutic GPCR and ion channel targets. […]
May 3, 2012

Integral Molecular Announces Patent Allowance for its Membrane Protein Lipoparticle Technology

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, a leader in membrane protein reagents and services, announces the issuance of a key patent protecting its methodology for generating Lipoparticles, which provide […]
April 25, 2012

Integral Molecular Announces Lipoparticle Distribution in Japan by Funakoshi

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, a leader in membrane protein reagents and services, announces an exclusive agreement with Funakoshi for the distribution of Integral Molecular’s catalog of concentrated […]
November 15, 2010

Integral Molecular to Expand its Headquarters at the Science Center in Philadelphia

PHILADELPHIA, PA, November 15, 2010 — Integral Molecular, Inc. and the University City Science Center announced today that Integral Molecular has signed a 10-year lease at […]
July 27, 2010

Integral Molecular Announces Key Patent Issued on Lipoparticle Technology for Deriving High Concentrations of Cell-free Membrane Proteins

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, Inc. today announced the issuance of a key patent covering its technology for deriving high concentrations of membrane proteins. The patent, issued by […]
November 3, 2009

Integral Molecular Awarded $9.1 Million Contract from NIAID to Map Epitopes on Viral Pathogens using Shotgun Mutagenesis Mapping Technology

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, Inc. has been selected to receive a five year, $9.1 million contract from the National Institute of Allergy and Infectious Disease (NIAID), part […]